...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current opinion in gastroenterology >Malignancies in inflammatory bowel disease
【24h】

Malignancies in inflammatory bowel disease

机译：炎症性肠病中的恶性肿瘤

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

hepatobiliary tract, and non-gastrointestinal tract cancers in inflammatory bowel disease remains of great interest. The purpose of this review is to report on studies published in 2002 that have addressed several important questions related to the biology, natural history, and risk factors for colonic and extracolonic cancers. Two studies reported conflicting results on the natural history of low-grade dysplasia in patients with ulcerative colitis. Other investigators focused on the safety of medications used to treat inflammatory bowel disease, one noting no increased risk of cancer with azathioprine, another suggesting that anti-tumor necrosis factor therapy may increase the risk of lymphoma. Studies of patients after total proctocolectomy and ileoanal pouch anastomosis suggest that these patients continue to have a small risk of bowel cancer. A novel observation from studies focusing on the subgroup of patients with inflammatory bowel disease and primary sclerosing cholangitis was the identification of an increased risk of pancreatic cancer. Finally, many investigators continue to pursue potential biomarkers of malignancy for use in inflammatory bowel disease cancer surveillance programs. These studies have added to our knowledge of the risk of malignancy in inflammatory bowel disease and have set the stage for future long-term studies to better delineate the risk of lymphoma with the use of anti-tumor necrosis factor therapy and the fate of low-grade dysplasia in flat mucosa. Clinical application of potential biomarkers of malignancy in inflammatory bowel disease cancer surveillance is anticipated in the near future.
机译：在炎性肠病中，肝胆道癌和非胃肠道癌仍然引起人们极大的兴趣。这篇综述的目的是报告2002年发表的研究，这些研究解决了与结肠癌和结肠外癌的生物学，自然史以及危险因素有关的几个重要问题。两项研究报告了溃疡性结肠炎患者低度不典型增生的自然史相互矛盾的结果。其他研究者集中于用于治疗炎性肠病的药物的安全性，一个注意到硫唑嘌呤不会增加患癌症的风险，另一个指出抗肿瘤坏死因子疗法可能会增加淋巴瘤的风险。对全结肠直肠切除术和回肠囊吻合术后患者的研究表明，这些患者继续患肠癌的风险较小。一项针对炎症性肠病和原发性硬化性胆管炎患者亚组的研究发现，一种新发现是胰腺癌风险增加。最后，许多研究者继续寻找潜在的恶性生物标志物，用于炎症性肠病癌症监测计划。这些研究增加了我们对炎症性肠病恶性肿瘤风险的认识，并为以后的长期研究奠定了基础，以便通过使用抗肿瘤坏死因子疗法和低血脂药物的命运更好地描述淋巴瘤的风险。扁平粘膜分级增生。预计在不久的将来，潜在的恶性生物标志物在炎症性肠病癌症监测中的临床应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号